30 Day Trial
BARE BONES logo

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Medicrea Growth Driven by U.S. Sales of Patient-Specific Implants -

Medicrea reported 3Q19 revenue of €8.2MM (USD $9.2MM), +12.3% vs. 3Q18.

 

  • Growth was driven by strength in key markets like the U.S. (+17.8%) and Belgium (+15%)
  • In 3Q19, 500 surgeries were performed with Medicrea patient-specific implants, representing a 57% increase overall vs. the prior year (+77% in the U.S.)
  • The company anticipates reaching the 5000th cumulative implant of their patient-specific rods by the end of 2019
  • ORTHOWORLD projects Medicrea full year 2019 revenue of $37.7MM, +4.3% vs. 2018

 

ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM).

  3Q19 3Q18 % Chg % Chg
Spine $7.7 $6.8 $0.9 13.0%
Orthobiologics $1.5 $1.4 $0.1 9.0%
Total $9.2 $8.2 $1.0 12.3%
  9Mo 19 9Mo 18 % Chg % Chg
Spine $22.7 $22.6 $0.1 0.6%
Orthobiologics $4.6 $4.6 $0.0 -0.6%
Total $27.3 $27.2 $0.1 0.4%

 

ORTHOWORLD estimates orthopaedic sales by geographic region as follows ($MM).

Geographic Region 3Q19 3Q18 % Chg % Chg
US $5.2 $4.4 $0.8 17.8%
Ex-US $4.0 $3.8 $0.2 5.9%
Total $9.2 $8.2 $1.0 12.3%

 

Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.